%PDF-1.6
%
1 0 obj
<>
endobj
2 0 obj
<>stream
Olav Dalgard, Ola Weiland, Geir Noraberg, Lars Karlsen, Lars Heggelund, Martti Färkkilâ, Ulla Balslev, Erika Belard, Anne Øvrehus, Mette Skalshøi Kjær, Henrik Krarup, Birgit Thorup Røge, Sofie Hallager, Lone G. Madsen, Alex Lund Laursen, Martin Lagging, Nina Weis
Sofosbuvir based treatment of chronic hepatitis C genotype 3 infections—A Scandinavian real-life study
www.plosone.org
www.plosone.org
endstream
endobj
3 0 obj
<>/XObject<>>>/CropBox[0 0 612 792]/MediaBox[0 0 612 792]/Parent 13 0 R/Annots 14 0 R/Contents 15 0 R/TrimBox[0 0 612 792]>>
endobj
14 0 obj
[16 0 R 17 0 R 18 0 R 19 0 R 20 0 R 21 0 R 22 0 R 23 0 R 24 0 R 25 0 R 26 0 R 27 0 R 28 0 R 29 0 R]
endobj
16 0 obj
<>/Border[0 0 0]/Dest(Rpone.0179764.ref001)>>
endobj
17 0 obj
<>/Border[0 0 0]/Dest(Rpone.0179764.ref002)>>
endobj
18 0 obj
<>/Border[0 0 0]/Dest(Rpone.0179764.ref003)>>
endobj
19 0 obj
<>/Border[0 0 0]/Dest(Rpone.0179764.ref004)>>
endobj
20 0 obj
<>/Border[0 0 0]/Dest(Rpone.0179764.ref005)>>
endobj
21 0 obj
<>/Border[0 0 0]/Dest(Rpone.0179764.ref006)>>
endobj
22 0 obj
<>/Border[0 0 0]/Dest(Rpone.0179764.ref007)>>
endobj
23 0 obj
<>/Border[0 0 0]/Dest(Rpone.0179764.ref008)>>
endobj
24 0 obj
<>/Border[0 0 0]/Dest(Rpone.0179764.ref009)>>
endobj
25 0 obj
<>/Border[0 0 0]/Dest(Rpone.0179764.ref010)>>
endobj
26 0 obj
<>/Border[0 0 0]/Dest(Rpone.0179764.ref011)>>
endobj
27 0 obj
<>/Border[0 0 0]/Dest(Rpone.0179764.ref012)>>
endobj
28 0 obj
<>/Border[0 0 0]/Dest(Rpone.0179764.ref013)>>
endobj
29 0 obj
<>/Border[0 0 0]/A 30 0 R>>
endobj
30 0 obj
<>
endobj
15 0 obj
[31 0 R 32 0 R 33 0 R 34 0 R 35 0 R 36 0 R 37 0 R 38 0 R 39 0 R 40 0 R 41 0 R 42 0 R 43 0 R 44 0 R 45 0 R 46 0 R]
endobj
31 0 obj
<>stream
q
0.45 0.36 0.35 0.01 k
0 w
575.9997 577.8196 m
199.9998 577.8196 l
199.9998 578.3196 l
575.9997 578.3196 l
f*
0.83 0.64 0.02 0 k
480.926 492.3213 m
485.6882 492.3213 l
h
f*
490.1102 492.3213 m
494.8724 492.3213 l
h
f*
377.2346 466.3559 m
381.9969 466.3559 l
h
f*
535.748 453.3165 m
540.5102 453.3165 l
h
f*
285.3354 414.3118 m
290.0976 414.3118 l
h
f*
299.1118 414.3118 m
303.874 414.3118 l
h
f*
556.7244 388.3465 m
561.4866 388.3465 l
h
f*
373.2661 362.3244 m
378.0283 362.3244 l
h
f*
343.0488 336.3591 m
347.811 336.3591 l
h
f*
241.1717 297.3543 m
250.6961 297.3543 l
h
f*
414.652 258.3496 m
424.1764 258.3496 l
h
f*
379.3323 232.3276 m
388.8567 232.3276 l
h
f*
393.3354 232.3276 m
402.8031 232.3276 l
h
f*
0 g
1 j
1 J
9.5 0 0 9.5 200.0125 707.7543 cm
BT
/F0 1 Tf
1 TL
-0.0042 Tc
0 0 Td
(\(91%\))Tj
2.8585 0 Td
(patients.)Tj
3.9565 0 Td
(Among)Tj
3.3598 0 Td
(26)Tj
1.3189 0 Td
(treatment)Tj
4.4101 0 Td
(failures,)Tj
3.676 0 Td
(five)Tj
1.7545 0 Td
(had)Tj
1.8679 0 Td
(non-response)Tj
6.0452 0 Td
(,)Tj
0.4953 0 Td
(3)Tj
0.7699 0 Td
(breakthrough)Tj
6.0392 0 Td
(and)Tj
1.8679 0 Td
(18)Tj
-38.4197 -1.474 Td
(relapse.)Tj
3.7297 0 Td
(Five)Tj
2.0947 0 Td
(patients)Tj
3.682 0 Td
(were)Tj
2.3632 0 Td
(not)Tj
1.5934 0 Td
(included)Tj
3.8909 0 Td
(in)Tj
0.9847 0 Td
(the)Tj
1.5933 0 Td
(mITT)Tj
2.5482 0 Td
(population.)Tj
5.0486 0 Td
(Three)Tj
2.8048 0 Td
(patients)Tj
3.6821 0 Td
(died)Tj
2.0827 0 Td
(from)Tj
-36.0983 -1.474 Td
(reasons)Tj
3.7357 0 Td
(unrelated)Tj
4.3325 0 Td
(to)Tj
1.0503 0 Td
(treatment)Tj
4.4042 0 Td
(and)Tj
1.8678 0 Td
(two)Tj
1.7605 0 Td
(were)Tj
2.3632 0 Td
(lost)Tj
1.7604 0 Td
(to)Tj
1.0444 0 Td
(follow-up.)Tj
4.4459 0 Td
(The)Tj
1.9275 0 Td
(SVR12)Tj
3.3598 0 Td
(rate)Tj
1.9276 0 Td
(was)Tj
1.9753 0 Td
(similar)Tj
-35.9551 -1.474 Td
(for)Tj
1.3725 0 Td
(all)Tj
1.1995 0 Td
(treatment)Tj
4.4041 0 Td
(regimens,)Tj
4.5653 0 Td
(but)Tj
1.5934 0 Td
(lower)Tj
2.572 0 Td
(in)Tj
0.9847 0 Td
(men)Tj
2.1483 0 Td
(\(p)Tj
1.0921 0 Td
(=)Tj
0.7997 0 Td
(0.042\),)Tj
3.3001 0 Td
(and)Tj
1.8619 0 Td
(in)Tj
0.9847 0 Td
(patients)Tj
3.682 0 Td
(with)Tj
1.9753 0 Td
(decompensated)Tj
-32.5356 -1.474 Td
(liver)Tj
2.023 0 Td
(disease)Tj
3.6224 0 Td
(\(p)Tj
1.098 0 Td
(=)Tj
0.7997 0 Td
(0.004\).)Tj
ET
Q
q
1 j
1 J
0 w
11.4998 0 0 11.4998 200.0125 622.3181 cm
BT
/F2 1 Tf
1 TL
-0.0035 Tc
0 0 Td
(Conclusion)Tj
ET
Q
q
1 j
1 J
0 w
9.5 0 0 9.5 200.0125 605.3102 cm
BT
/F0 1 Tf
1 TL
-0.0042 Tc
0 0 Td
(We)Tj
1.7067 0 Td
(found)Tj
2.6914 0 Td
(that)Tj
1.8679 0 Td
(sofosbuvir)Tj
4.7204 0 Td
(based)Tj
2.9063 0 Td
(treatment)Tj
4.4041 0 Td
(in)Tj
0.9787 0 Td
(a)Tj
0.7638 0 Td
(real-life)Tj
3.4434 0 Td
(setting)Tj
3.127 0 Td
(could)Tj
2.5721 0 Td
(offer)Tj
2.1961 0 Td
(SVR)Tj
2.2617 0 Td
(rates)Tj
2.4169 0 Td
(exceed-)Tj
-36.0565 -1.474 Td
(ing)Tj
1.5336 0 Td
(90%)Tj
2.1961 0 Td
(in)Tj
0.9847 0 Td
(patients)Tj
3.682 0 Td
(with)Tj
1.9753 0 Td
(HCV)Tj
2.3155 0 Td
(genotype)Tj
4.2848 0 Td
(3)Tj
0.7698 0 Td
(infection)Tj
3.8969 0 Td
(and)Tj
1.8678 0 Td
(advanced)Tj
4.5056 0 Td
(liver)Tj
2.0231 0 Td
(disease.)Tj
ET
Q
q
1 j
1 J
0 w
11.9999 0 0 11.9999 200.0125 523.3889 cm
BT
/F2 1 Tf
1 TL
-0.0033 Tc
0 0 Td
(Introduction)Tj
ET
Q
q
1 j
1 J
0 w
10 0 0 10 200.0125 506.3811 cm
BT
/F7 1 Tf
1 TL
-0.004 Tc
0 0 Td
(Approximately)Tj
6.2248 0 Td
(100,000)Tj
3.2995 0 Td
(individuals)Tj
4.6488 0 Td
(are)Tj
1.4456 0 Td
(infected)Tj
3.4243 0 Td
(with)Tj
1.9956 0 Td
(hepatitis)Tj
3.6169 0 Td
(C)Tj
0.8788 0 Td
(virus)Tj
2.2053 0 Td
(\(HCV\))Tj
3.0217 0 Td
(in)Tj
1.0375 0 Td
(Scandinavia)Tj
-31.7988 -1.2982 Td
(\(Denmark,)Tj
4.6147 0 Td
(Finland,)Tj
3.5433 0 Td
(Norway,)Tj
3.634 0 Td
(Sweden\))Tj
3.6453 0 Td
(of)Tj
1.0148 0 Td
(whom)Tj
2.7553 0 Td
(50%)Tj
1.9275 0 Td
(have)Tj
2.0636 0 Td
(genotype)Tj
3.8551 0 Td
(3)Tj
0.6974 0 Td
([)Tj
0.83 0.64 0.02 0 k
(1)Tj
0 g
(,)Tj
0.83 0.64 0.02 0 k
1.2585 0 Td
(2)Tj
0 g
(].)Tj
1.2643 0 Td
(Patients)Tj
3.4072 0 Td
(with)Tj
-33.681 -1.2983 Td
(HCV)Tj
2.3414 0 Td
(genotype)Tj
3.8607 0 Td
(3)Tj
0.6973 0 Td
(seem)Tj
2.2451 0 Td
(to)Tj
1.0261 0 Td
(have)Tj
2.0579 0 Td
(a)Tj
0.6577 0 Td
(more)Tj
2.3414 0 Td
(rapid)Tj
2.3357 0 Td
(progression)Tj
4.9209 0 Td
(to)Tj
1.0262 0 Td
(cirrhosis)Tj
3.6736 0 Td
(and)Tj
1.7292 0 Td
(its)Tj
1.1508 0 Td
(complications)Tj
-30.064 -1.2982 Td
(than)Tj
2.0295 0 Td
(patients)Tj
3.3676 0 Td
(infected)Tj
3.4185 0 Td
(with)Tj
1.9956 0 Td
(other)Tj
2.3471 0 Td
(genotypes)Tj
4.2236 0 Td
([)Tj
0.83 0.64 0.02 0 k
(3)Tj
0 g
(].)Tj
-16.1857 -1.304 Td
(Since)Tj
2.3584 0 Td
(2011)Tj
2.1259 0 Td
(new)Tj
1.8766 0 Td
(direct)Tj
2.5285 0 Td
(acting)Tj
2.6588 0 Td
(antivirals)Tj
3.9005 0 Td
(\(DAAs\))Tj
3.3675 0 Td
(against)Tj
3.0274 0 Td
(HCV)Tj
2.3471 0 Td
(have)Tj
2.0579 0 Td
(been)Tj
2.1203 0 Td
(available)Tj
3.668 0 Td
([)Tj
0.83 0.64 0.02 0 k
(4)Tj
0 g
(].)Tj
1.6044 0 Td
(The)Tj
-34.8375 -1.2982 Td
(first)Tj
1.8028 0 Td
(generation)Tj
4.507 0 Td
(protease)Tj
3.5547 0 Td
(inhibitors)Tj
4.1442 0 Td
(lacked)Tj
2.7722 0 Td
(effect)Tj
2.3641 0 Td
(against)Tj
3.0274 0 Td
(genotype)Tj
3.8608 0 Td
(3)Tj
0.6916 0 Td
(whereas)Tj
3.4469 0 Td
(the)Tj
1.4684 0 Td
(nucleotide)Tj
-31.6401 -1.2983 Td
(analogue)Tj
3.804 0 Td
(NS5B)Tj
2.4888 0 Td
(polymerase)Tj
4.7792 0 Td
(inhibitor)Tj
3.7814 0 Td
(sofosbuvir)Tj
4.371 0 Td
(\(SOF\))Tj
2.6475 0 Td
(had)Tj
1.7122 0 Td
(pan-genotypic)Tj
5.9753 0 Td
(activity)Tj
3.1181 0 Td
(including)Tj
-32.6775 -1.3039 Td
(effect)Tj
2.364 0 Td
(on)Tj
1.2756 0 Td
(genotype)Tj
3.8551 0 Td
(3)Tj
0.6973 0 Td
([)Tj
0.83 0.64 0.02 0 k
(5)Tj
0 g
(])Tj
1.3777 0 Td
([)Tj
0.83 0.64 0.02 0 k
(6)Tj
0 g
(].)Tj
1.5987 0 Td
(SOF)Tj
1.9729 0 Td
(given)Tj
2.3754 0 Td
(during)Tj
2.931 0 Td
(24)Tj
1.1679 0 Td
(weeks)Tj
2.6135 0 Td
(in)Tj
1.0318 0 Td
(combination)Tj
5.3461 0 Td
(with)Tj
2.0013 0 Td
(ribavirin)Tj
3.7077 0 Td
(\(RBV\))Tj
-34.316 -1.2983 Td
(for)Tj
1.3832 0 Td
(genotype)Tj
3.8608 0 Td
(3)Tj
0.6973 0 Td
(infections)Tj
4.1499 0 Td
(offered)Tj
3.0501 0 Td
(sustained)Tj
3.9685 0 Td
(virologic)Tj
3.7303 0 Td
(response)Tj
3.7304 0 Td
(\(SVR\))Tj
2.6929 0 Td
(12)Tj
1.1679 0 Td
(weeks)Tj
2.6135 0 Td
(after)Tj
2.0353 0 Td
(end)Tj
1.7177 0 Td
(of)Tj
-34.7978 -1.2982 Td
(treatment)Tj
4.1328 0 Td
(\(SVR12\))Tj
3.6454 0 Td
(in)Tj
1.0374 0 Td
(90%)Tj
1.9276 0 Td
(of)Tj
1.0148 0 Td
(non-cirrhotic)Tj
5.6296 0 Td
(patients)Tj
3.3675 0 Td
(but)Tj
1.5534 0 Td
(in)Tj
1.0374 0 Td
(only)Tj
1.9729 0 Td
(60%)Tj
1.9333 0 Td
(in)Tj
1.0318 0 Td
(cirrhotic)Tj
3.6793 0 Td
(patients)Tj
3.3676 0 Td
([)Tj
0.83 0.64 0.02 0 k
(7)Tj
0 g
(].)Tj
-34.1346 -1.304 Td
(In)Tj
1.1111 0 Td
(vitro)Tj
2.1203 0 Td
(studies)Tj
2.9821 0 Td
(with)Tj
2.0012 0 Td
(the)Tj
1.4684 0 Td
(NS5A)Tj
2.5908 0 Td
(inhibitor)Tj
3.7814 0 Td
(daclatasvir)Tj
4.473 0 Td
(\(DCV\))Tj
2.9934 0 Td
(also)Tj
1.7688 0 Td
(indicated)Tj
3.9345 0 Td
(high)Tj
2.0126 0 Td
(efficacy)Tj
-32.4338 -1.2982 Td
(against)Tj
3.0273 0 Td
(all)Tj
1.1452 0 Td
(genotypes)Tj
4.2179 0 Td
(including)Tj
4.0422 0 Td
(genotype)Tj
3.8608 0 Td
(3)Tj
0.6916 0 Td
([)Tj
0.83 0.64 0.02 0 k
(8)Tj
0 g
(].)Tj
1.6044 0 Td
(In)Tj
1.1055 0 Td
(the)Tj
1.4741 0 Td
(ALLY-3)Tj
3.4355 0 Td
(study)Tj
2.3924 0 Td
(SOF+DCV)Tj
4.6432 0 Td
(without)Tj
3.3278 0 Td
(RBV)Tj
-34.9679 -1.2983 Td
(was)Tj
1.6951 0 Td
(given)Tj
2.381 0 Td
(for)Tj
1.389 0 Td
(12)Tj
1.1679 0 Td
(weeks)Tj
2.6078 0 Td
(and)Tj
1.7348 0 Td
(yielded)Tj
3.0898 0 Td
(SVR12)Tj
2.9593 0 Td
(in)Tj
1.0375 0 Td
(94%)Tj
1.9275 0 Td
(in)Tj
1.0375 0 Td
(non-cirrhotic)Tj
5.6296 0 Td
(genotype)Tj
3.8608 0 Td
(3)Tj
0.6916 0 Td
(patients)Tj
3.3732 0 Td
(but)Tj
-34.5824 -1.2982 Td
(only)Tj
1.9729 0 Td
(in)Tj
1.0374 0 Td
(63%)Tj
1.9276 0 Td
(of)Tj
1.0148 0 Td
(those)Tj
2.3414 0 Td
(with)Tj
1.9955 0 Td
(cirrhosis)Tj
3.6737 0 Td
([)Tj
0.83 0.64 0.02 0 k
(9)Tj
0 g
(].)Tj
1.6044 0 Td
(In)Tj
1.1055 0 Td
(the)Tj
1.474 0 Td
(ALLY-3+)Tj
4.0139 0 Td
(study,)Tj
2.6192 0 Td
(SOF+DCV+RBV)Tj
7.1206 0 Td
(was)Tj
1.6951 0 Td
(given)Tj
2.381 0 Td
(for)Tj
-35.977 -1.304 Td
(12)Tj
1.1678 0 Td
(or)Tj
1.0999 0 Td
(16)Tj
1.1735 0 Td
(weeks,)Tj
2.8346 0 Td
(to)Tj
1.0205 0 Td
(treatment)Tj
4.1385 0 Td
(na)Tj
/F11 1 Tf
[()]TJ
/F7 1 Tf
(ve)Tj
2.3358 0 Td
(and)Tj
1.7291 0 Td
(experienced)Tj
5.0343 0 Td
(patients)Tj
3.3732 0 Td
(with)Tj
1.9956 0 Td
(stage)Tj
2.1997 0 Td
(F3-F4)Tj
2.5795 0 Td
(fibrosis,)Tj
3.3732 0 Td
(and)Tj
1.7291 0 Td
(SVR)Tj
-35.7843 -1.2982 Td
(was)Tj
1.6951 0 Td
(achieved)Tj
3.702 0 Td
(in)Tj
1.0375 0 Td
(31/36)Tj
2.4547 0 Td
(\(86%\))Tj
2.6079 0 Td
(of)Tj
1.0148 0 Td
(F4)Tj
1.2246 0 Td
(patients)Tj
3.3675 0 Td
(with)Tj
1.9956 0 Td
(no)Tj
1.2756 0 Td
(improvement)Tj
5.6692 0 Td
(with)Tj
2.0013 0 Td
(treatment)Tj
4.1328 0 Td
(prolonged)Tj
4.3314 0 Td
(to)Tj
-36.51 -1.2983 Td
(16)Tj
1.1678 0 Td
(weeks)Tj
2.6079 0 Td
([)Tj
0.83 0.64 0.02 0 k
(10)Tj
0 g
(].)Tj
-2.5795 -1.3039 Td
(A)Tj
0.907 0 Td
(second)Tj
3.0104 0 Td
(NS5A)Tj
2.5909 0 Td
(inhibitor,)Tj
4.0081 0 Td
(ledipasvir)Tj
4.0876 0 Td
(\(LDV\))Tj
2.8686 0 Td
(has)Tj
1.5477 0 Td
(been)Tj
2.1203 0 Td
(combined)Tj
4.2406 0 Td
(with)Tj
2.0013 0 Td
(SOF)Tj
1.9672 0 Td
(in)Tj
1.0375 0 Td
(a)Tj
0.6519 0 Td
(fixed)Tj
2.194 0 Td
(dose)Tj
-34.4293 -1.2983 Td
(combination)Tj
5.3461 0 Td
(\(FDC\))Tj
2.8289 0 Td
(tablet,)Tj
2.6532 0 Td
(administered)Tj
5.4879 0 Td
(once)Tj
2.1203 0 Td
(daily.)Tj
2.3754 0 Td
(This)Tj
1.9899 0 Td
(therapy)Tj
3.2485 0 Td
(is)Tj
0.8447 0 Td
(highly)Tj
2.7099 0 Td
(effective)Tj
3.5093 0 Td
(against)Tj
-33.1141 -1.2982 Td
(HCV)Tj
2.3414 0 Td
(genotype)Tj
3.8607 0 Td
(1)Tj
0.6973 0 Td
(infections,)Tj
4.3767 0 Td
(also)Tj
1.7688 0 Td
(in)Tj
1.0318 0 Td
(cirrhotic)Tj
3.6794 0 Td
(patients)Tj
3.3675 0 Td
([)Tj
0.83 0.64 0.02 0 k
(11)Tj
0 g
(].)Tj
2.0749 0 Td
(Little)Tj
2.2961 0 Td
(data)Tj
1.9105 0 Td
(have)Tj
2.0636 0 Td
(been)Tj
2.1203 0 Td
(published)Tj
4.1273 0 Td
(for)Tj
-35.7163 -1.304 Td
(genotype)Tj
3.855 0 Td
(3)Tj
0.6974 0 Td
(infections,)Tj
4.3766 0 Td
(but)Tj
1.5534 0 Td
(both)Tj
2.0636 0 Td
(in)Tj
1.0318 0 Td
(vitro)Tj
2.1203 0 Td
(studies)Tj
2.9877 0 Td
(and)Tj
1.7291 0 Td
(phase)Tj
2.4832 0 Td
(2)Tj
0.6973 0 Td
(studies)Tj
2.982 0 Td
(indicate)Tj
3.4129 0 Td
(that)Tj
1.7745 0 Td
(LDV)Tj
2.194 0 Td
(is)Tj
0.8447 0 Td
(less)Tj
-34.8035 -1.2982 Td
(effective)Tj
3.5092 0 Td
(than)Tj
2.0296 0 Td
(DCV)Tj
2.3131 0 Td
(in)Tj
1.0374 0 Td
(genotype)Tj
3.8551 0 Td
(3)Tj
0.6974 0 Td
(infections)Tj
4.1499 0 Td
([)Tj
0.83 0.64 0.02 0 k
(12)Tj
0 g
(,)Tj
0.83 0.64 0.02 0 k
1.7404 0 Td
(13)Tj
0 g
(].)Tj
-18.1359 -1.2983 Td
(The)Tj
1.7858 0 Td
(aim)Tj
1.7404 0 Td
(of)Tj
1.0148 0 Td
(this)Tj
1.6725 0 Td
(study)Tj
2.3924 0 Td
(was)Tj
1.6951 0 Td
(to)Tj
1.0261 0 Td
(document)Tj
4.2973 0 Td
(the)Tj
1.4684 0 Td
(effect)Tj
2.364 0 Td
(of)Tj
1.0148 0 Td
(sofosbuvir)Tj
4.371 0 Td
(based)Tj
2.4775 0 Td
(regimens)Tj
3.9005 0 Td
(in)Tj
1.0318 0 Td
(patients)Tj
-33.4486 -1.3039 Td
(treated)Tj
2.9933 0 Td
(for)Tj
1.389 0 Td
(HCV)Tj
2.3471 0 Td
(genotype)Tj
3.8551 0 Td
(3)Tj
0.6973 0 Td
(infection)Tj
3.7927 0 Td
(in)Tj
1.0318 0 Td
(a)Tj
0.6576 0 Td
(real)Tj
1.6951 0 Td
(life)Tj
1.44 0 Td
(setting)Tj
2.8857 0 Td
(in)Tj
1.0375 0 Td
(Scandinavia.)Tj
ET
Q
q
1 j
1 J
0 w
11.9999 0 0 11.9999 200.0125 178.0157 cm
BT
/F2 1 Tf
1 TL
-0.0033 Tc
0 0 Td
(Materials)Tj
4.5071 0 Td
(and)Tj
1.989 0 Td
(methods)Tj
ET
Q
q
1 j
1 J
0 w
10 0 0 10 200.0125 161.0078 cm
BT
/F7 1 Tf
1 TL
-0.004 Tc
0 0 Td
(This)Tj
1.9842 0 Td
(retrospective,)Tj
5.5899 0 Td
(multicenter)Tj
4.8642 0 Td
(cohort)Tj
2.8573 0 Td
(study)Tj
2.3868 0 Td
(included)Tj
3.7133 0 Td
(HCV)Tj
2.3471 0 Td
(genotype)Tj
3.8551 0 Td
(3)Tj
0.6973 0 Td
(infected)Tj
3.4186 0 Td
(patients)Tj
/F12 1 Tf
0 Tc
3.3675 0 Td
()Tj
/F7 1 Tf
-0.004 Tc
(18)Tj
-35.0813 -1.2982 Td
(years)Tj
2.262 0 Td
(of)Tj
1.0148 0 Td
(age)Tj
1.542 0 Td
(old)Tj
1.5024 0 Td
(who)Tj
1.9389 0 Td
(had)Tj
1.7121 0 Td
(received)Tj
3.5319 0 Td
(at)Tj
0.9525 0 Td
(least)Tj
1.9842 0 Td
(one)Tj
1.7008 0 Td
(dose)Tj
2.0352 0 Td
(of)Tj
1.0148 0 Td
(SOF)Tj
1.9729 0 Td
(in)Tj
1.0318 0 Td
(Denmark,)Tj
4.2747 0 Td
(Norway,)Tj
3.6339 0 Td
(Finland)Tj
3.3222 0 Td
(or)Tj
-35.4271 -1.3039 Td
(Sweden.)Tj
3.5262 0 Td
(Organ)Tj
2.7893 0 Td
(transplanted)Tj
5.2271 0 Td
(and)Tj
1.7291 0 Td
(HIV)Tj
2.0239 0 Td
(or)Tj
1.0998 0 Td
(HBV)Tj
2.2564 0 Td
(co-infected)Tj
4.7055 0 Td
(patients)Tj
3.3675 0 Td
(were)Tj
2.1203 0 Td
(excluded.)Tj
4.0139 0 Td
(If)Tj
0.8447 0 Td
(patients)Tj
-33.7037 -1.2983 Td
(had)Tj
1.7064 0 Td
(received)Tj
3.5376 0 Td
(treatment)Tj
4.1329 0 Td
(with)Tj
2.0012 0 Td
(a)Tj
0.652 0 Td
(SOF)Tj
1.9672 0 Td
(containing)Tj
4.5298 0 Td
(regime)Tj
2.9933 0 Td
(more)Tj
2.3414 0 Td
(than)Tj
2.024 0 Td
(once,)Tj
2.3527 0 Td
(only)Tj
1.9729 0 Td
(the)Tj
1.4684 0 Td
(first)Tj
1.8084 0 Td
(treatment)Tj
-33.4882 -1.2983 Td
(was)Tj
1.6894 0 Td
(included)Tj
3.702 0 Td
(in)Tj
1.0261 0 Td
(the)Tj
1.457 0 Td
(present)Tj
3.1578 0 Td
(analysis.)Tj
3.5433 0 Td
(In)Tj
1.0998 0 Td
(Sweden)Tj
3.2939 0 Td
(the)Tj
1.457 0 Td
(Regional)Tj
3.7247 0 Td
(Ethical)Tj
2.9763 0 Td
(Review)Tj
3.0841 0 Td
(Board,)Tj
2.8573 0 Td
(Stockholm,)Tj
-33.0687 -1.3039 Td
(Sweden)Tj
3.2995 0 Td
(\(Regionala)Tj
4.507 0 Td
(etikpro)Tj
0 Tc
2.4378 0 Td
()Tj
-0.004 Tc
0.4479 0 Td
(vningsna)Tj
0 Tc
3.2144 0 Td
()Tj
-0.004 Tc
0.4082 0 Td
(mnden)Tj
3.0898 0 Td
(i)Tj
0.4875 0 Td
(Stockholm\))Tj
4.8642 0 Td
(and)Tj
1.7292 0 Td
(Regional)Tj
3.7303 0 Td
(Ethical)Tj
2.9877 0 Td
(Review)Tj
3.0954 0 Td
(Board,)Tj
-34.2989 -1.2982 Td
(Gothenburg,)Tj
5.3347 0 Td
(Sweden)Tj
3.3052 0 Td
(\(Regionala)Tj
4.5071 0 Td
(etikpro)Tj
0 Tc
2.4377 0 Td
()Tj
-0.004 Tc
0.4422 0 Td
(vningsna)Tj
0 Tc
3.2145 0 Td
()Tj
-0.004 Tc
0.4139 0 Td
(mnden)Tj
3.0897 0 Td
(i)Tj
0.4876 0 Td
(Go)Tj
0 Tc
0.7766 0 Td
()Tj
-0.004 Tc
0.4422 0 Td
(teborg\))Tj
3.1351 0 Td
(reviewed)Tj
3.7928 0 Td
(to)Tj
1.0261 0 Td
(the)Tj
1.4684 0 Td
(study)Tj
ET
Q
q
1 j
1 J
0 w
576 737.1 m
36 737.1 l
36 737.6 l
576 737.6 l
f*
36 741.2598 107.1496 23.6976 re
W* n
q
107.0929 0 0 23.6409 36 741.3165 cm
q
/I0 Do
Q
Q
Q
q
0 0 612 792 re
W* n
1 j
1 J
0 w
7.9999 0 0 7.9999 374.1732 745.7952 cm
BT
/F0 1 Tf
1 TL
-0.005 Tc
0 0 Td
(Sofosbuvi)Tj
4.3157 0 Td
(r)Tj
0.5457 0 Td
(contianin)Tj
3.9189 0 Td
(g)Tj
0.7654 0 Td
(regimes)Tj
3.7205 0 Td
(in)Tj
0.978 0 Td
(HCV)Tj
2.3031 0 Td
(genotype)Tj
4.2591 0 Td
(3)Tj
0.7654 0 Td
(infection)Tj
ET
Q
q
1 j
1 J
0 w
36 48.0002 m
576 48.0002 l
576 47.5002 l
36 47.5002 l
f*
0.83 0.64 0.02 0 k
81.5811 34.9228 m
237.8835 34.9228 l
h
f*
0 g
7.9999 0 0 7.9999 36 36 cm
BT
/F0 1 Tf
1 TL
-0.005 Tc
0 0 Td
(PLOS)Tj
2.8559 0 Td
(ONE)Tj
2.3669 0 Td
(|)Tj
0.83 0.64 0.02 0 k
0.4748 0 Td
(https://doi.or)Tj
5.4142 0 Td
(g/10.137)Tj
3.8198 0 Td
(1/journal.po)Tj
5.1236 0 Td
(ne.01797)Tj
4.089 0 Td
(64)Tj
0 g
2.0906 0 Td
(July)Tj
1.9701 0 Td
(13,)Tj
1.5874 0 Td
(2017)Tj
35.894 0 Td
(2)Tj
0.7654 0 Td
(/)Tj
0.496 0 Td
(8)Tj
/F8 1 Tf
-0.025 Tc
-66.9477 84.0904 Td
(Funding:)Tj
/F9 1 Tf
3.5716 0 Td
(The)Tj
1.5874 0 Td
(author\(s\))Tj
3.6639 0 Td
(received)Tj
3.2953 0 Td
(no)Tj
1.1693 0 Td
(specific)Tj
-13.2875 -1.3748 Td
(funding)Tj
3.033 0 Td
(for)Tj
1.2615 0 Td
(this)Tj
1.559 0 Td
(work.)Tj
/F8 1 Tf
-5.8535 -2.126 Td
(Competing)Tj
4.3795 0 Td
(interests)Tj
3.3307 0 Td
(:)Tj
/F9 1 Tf
0.4819 0 Td
(Olav)Tj
1.8426 0 Td
(Dalgard:)Tj
3.3165 0 Td
(Research)Tj
-13.3512 -1.3749 Td
(grants)Tj
2.5724 0 Td
(Gilead,)Tj
2.7355 0 Td
(Abbvie)Tj
2.7283 0 Td
(and)Tj
1.5874 0 Td
(Merck.)Tj
2.7709 0 Td
(Paid)Tj
1.8284 0 Td
(lectures)Tj
-14.2229 -1.3748 Td
(Abbvie,)Tj
2.9551 0 Td
(Merck)Tj
2.5441 0 Td
(and)Tj
1.5874 0 Td
(Gilead.)Tj
2.7355 0 Td
(Chair)Tj
2.1401 0 Td
(of)Tj
0.9497 0 Td
(committe)Tj
3.522 0 Td
(e)Tj
-16.4339 -1.3748 Td
(writing)Tj
2.7567 0 Td
(Norwegian)Tj
4.2094 0 Td
(national)Tj
3.1253 0 Td
(guidelines)Tj
3.9543 0 Td
(for)Tj
1.2544 0 Td
(HCV)Tj
-15.3001 -1.3748 Td
(treatment)Tj
3.7842 0 Td
(in)Tj
0.8859 0 Td
(Norway.)Tj
3.2953 0 Td
(Nina)Tj
1.8992 0 Td
(Weis:)Tj
2.2819 0 Td
(Clinical)Tj
-12.1465 -1.3748 Td
(investigator)Tj
4.3086 0 Td
(,)Tj
0.4465 0 Td
(speaker)Tj
3.104 0 Td
(and)Tj
1.5945 0 Td
(advisory)Tj
3.352 0 Td
(board)Tj
2.3669 0 Td
(member)Tj
-15.1725 -1.3748 Td
(for)Tj
1.2543 0 Td
(Abbvie,)Tj
2.9551 0 Td
(Bristol)Tj
2.5867 0 Td
(Myers)Tj
2.5441 0 Td
(Squibb)Tj
2.8346 0 Td
(and)Tj
1.5875 0 Td
(Merck)Tj
2.5441 0 Td
(Sharp)Tj
-16.3064 -1.3748 Td
(&)Tj
0.8574 0 Td
(Dohme;)Tj
3.1536 0 Td
(speaker)Tj
3.1111 0 Td
(and)Tj
1.5874 0 Td
(advisory)Tj
3.352 0 Td
(board)Tj
2.3669 0 Td
(member)Tj
3.352 0 Td
(for)Tj
-17.7804 -1.3749 Td
(Gilead.)Tj
2.7354 0 Td
(Lars)Tj
1.8425 0 Td
(Karlsen:)Tj
3.2103 0 Td
(Advisory)Tj
3.4512 0 Td
(boards:)Tj
3.0189 0 Td
(Merck,)Tj
-14.2583 -1.3748 Td
(Abbvie,)Tj
2.9551 0 Td
(Gilead,)Tj
2.7284 0 Td
(Bristol-Myers)Tj
5.2228 0 Td
(Squibb.)Tj
3.0615 0 Td
(Member)Tj
3.3449 0 Td
(of)Tj
-17.3127 -1.3748 Td
(the)Tj
1.3677 0 Td
(committee)Tj
4.174 0 Td
(that)Tj
1.6229 0 Td
(write)Tj
2.0338 0 Td
(national)Tj
3.1253 0 Td
(guidelines)Tj
3.9614 0 Td
(for)Tj
-16.2851 -1.3748 Td
(HCV)Tj
1.8567 0 Td
(treatment)Tj
3.7842 0 Td
(in)Tj
0.8859 0 Td
(Norway)Tj
3.0756 0 Td
(Clinical)Tj
2.8347 0 Td
(expert)Tj
2.5157 0 Td
(in)Tj
0.8859 0 Td
(HCV)Tj
1.8638 0 Td
(for)Tj
-17.7025 -1.3748 Td
(The)Tj
1.5874 0 Td
(Norwegian)Tj
4.2094 0 Td
(Medicines)Tj
3.9969 0 Td
(Agency)Tj
2.9552 0 Td
(Martti)Tj
2.4024 0 Td
(Fa)Tj
0 Tc
0.4889 0 Td
()Tj
-0.025 Tc
0.3544 0 Td
(rkkila:)Tj
-15.9946 -1.3748 Td
(Study)Tj
2.3669 0 Td
(grant:)Tj
2.374 0 Td
(Gilead.)Tj
2.7355 0 Td
(Speaker)Tj
3.2173 0 Td
(and)Tj
1.5874 0 Td
(consultati)Tj
3.5788 0 Td
(on)Tj
1.1693 0 Td
(fee,)Tj
-17.0292 -1.3748 Td
(MSD)Tj
2.0834 0 Td
(Finland,)Tj
3.0969 0 Td
(Janssen,)Tj
3.5008 0 Td
(BMS,)Tj
2.2465 0 Td
(Takeda,)Tj
3.0756 0 Td
(Pfizer,)Tj
2.5087 0 Td
(Cook)Tj
-16.5119 -1.3748 Td
(Ireland,)Tj
2.9905 0 Td
(Intercept)Tj
3.5008 0 Td
(Ola)Tj
1.4245 0 Td
(Weiland:)Tj
3.4228 0 Td
(Consultancie)Tj
4.7481 0 Td
(s:)Tj
-16.0867 -1.3749 Td
(AbbVie,)Tj
3.0543 0 Td
(BMS,)Tj
2.2536 0 Td
(Gilead,)Tj
2.7283 0 Td
(Janssen,)Tj
3.5008 0 Td
(Medivir,)Tj
3.2103 0 Td
(Roche)Tj
2.5937 0 Td
(and)Tj
-17.341 -1.3748 Td
(MSD/Merc)Tj
4.0252 0 Td
(k.)Tj
0.8646 0 Td
(Speaker's)Tj
3.8268 0 Td
(bureau:)Tj
3.0189 0 Td
(AbbVie,)Tj
3.0543 0 Td
(BMS,)Tj
-14.7898 -1.3748 Td
(Gilead,)Tj
2.7354 0 Td
(Janssen,)Tj
3.4937 0 Td
(Medivir,)Tj
3.2103 0 Td
(Roche)Tj
2.6008 0 Td
(and)Tj
1.5874 0 Td
(MSD/Mer)Tj
3.6 0 Td
(ck)Tj
-17.2276 -1.3748 Td
(Lone)Tj
2.0622 0 Td
(Madsen:)Tj
3.4087 0 Td
(Lecture)Tj
2.9905 0 Td
(fees)Tj
1.7434 0 Td
(from:)Tj
2.2323 0 Td
(BMS)Tj
2.0267 0 Td
(and)Tj
-14.4638 -1.3748 Td
(Medivir.)Tj
3.2102 0 Td
(Advisory)Tj
3.4512 0 Td
(Board)Tj
2.4237 0 Td
(member:)Tj
3.5787 0 Td
(AbbVie)Tj
2.8276 0 Td
(and)Tj
-15.4914 -1.3748 Td
(BMS.)Tj
2.2464 0 Td
(Mette)Tj
2.3315 0 Td
(Kjr:)Tj
2.1048 0 Td
(Speakers)Tj
3.6354 0 Td
(fee)Tj
1.3182 0 Td
(from)Tj
2.0126 0 Td
(Abbvie.)Tj
2.948 0 Td
(This)Tj
-16.5969 -1.3819 Td
(does)Tj
2.0126 0 Td
(not)Tj
1.4173 0 Td
(alter)Tj
1.8213 0 Td
(our)Tj
1.474 0 Td
(adherence)Tj
4.0536 0 Td
(to)Tj
0.9496 0 Td
(PLOS)Tj
2.3315 0 Td
(ONE)Tj
1.8709 0 Td
(policies)Tj
-15.9308 -1.3748 Td
(on)Tj
1.1693 0 Td
(sharing)Tj
2.9834 0 Td
(data)Tj
1.7859 0 Td
(and)Tj
1.5945 0 Td
(material)Tj
ET
endstream
endobj
32 0 obj
<>stream
endstream
endobj
33 0 obj
<>stream
endstream
endobj
34 0 obj
<>stream
endstream
endobj
35 0 obj
<>stream
endstream
endobj
36 0 obj
<>stream
endstream
endobj
37 0 obj
<>stream
endstream
endobj
38 0 obj
<>stream
endstream
endobj
39 0 obj
<>stream
endstream
endobj
40 0 obj
<>stream
endstream
endobj
41 0 obj
<>stream
endstream
endobj
42 0 obj
<>stream
endstream
endobj
43 0 obj
<>stream
endstream
endobj
44 0 obj
<>stream
endstream
endobj
45 0 obj
<>stream
endstream
endobj
46 0 obj
<>stream
BT
10.4953 48.9618 Td
(s.)Tj
ET
Q
endstream
endobj
47 0 obj
<>/XObject<>>>/CropBox[0 0 612 792]/MediaBox[0 0 612 792]/Parent 13 0 R/Annots 50 0 R/Contents 51 0 R/TrimBox[0 0 612 792]>>
endobj
48 0 obj
<>
endobj
52 0 obj
<>stream
/CIDInit/ProcSet findresource begin
12 dict begin begincmap
/CMapName/Adobe-Identity-UCS def
/CIDSystemInfo<>def
/CMapType 2 def
1 begincodespacerange
<0000>
endcodespacerange
1 beginbfchar
<010B><03B1>
endbfchar
endcmap
CMapName currentdict /CMap defineresource pop end end
endstream
endobj
53 0 obj
<>/FontDescriptor 54 0 R/DW 250/W[267[578]]>>
endobj
54 0 obj
<>
endobj
55 0 obj
<>stream
cvt f6 fpgm2Msf bglyf屎c headp# 6hhea1 $hmtx&O